Form 8-K - Current report:
SEC Accession No. 0001193125-26-253436
Filing Date
2026-06-02
Accepted
2026-06-02 16:01:14
Documents
12
Period of Report
2026-05-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d110060d8k.htm   iXBRL 8-K 44789
2 EX-10.1 d110060dex101.htm EX-10.1 94641
  Complete submission text file 0001193125-26-253436.txt   282316

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20260529.xsd EX-101.SCH 3186
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20260529_lab.xml EX-101.LAB 17992
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20260529_pre.xml EX-101.PRE 11265
15 EXTRACTED XBRL INSTANCE DOCUMENT d110060d8k_htm.xml XML 3629
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 261055756
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)